The company specializes in creating cell-based therapies that target corneal blindness. StemSight's approach involves utilizing allogeneic human induced pluripotent stem cells (hiPSCs) and advanced ophthalmic applications and culture methods to treat bilateral or unilateral limbal stem cell deficiency (LSCD). By leveraging these solutions, StemSight aims to help patients suffering from corneal blindness regain their vision.